🇺🇸 FDA
Pipeline program

TRU-016

16011

Phase 1 small_molecule completed

Quick answer

TRU-016 for B-cell Small Lymphocytic Lymphoma Recurrent is a Phase 1 program (small_molecule) at Aptevo Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aptevo Therapeutics
Indication
B-cell Small Lymphocytic Lymphoma Recurrent
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials